This targeted delivery system resulted in significant tumor growth inhibition in a mouse model of EGFR+ cancer, suggesting that PD-L1 targeting in TAMs offers a promising therapeutic strategy for enhancing ICB efficacy [168]. The gene discussed is EGFR; the disease is cancer.